UK markets closed
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • FTSE 250

    18,279.42
    +180.74 (+1.00%)
     
  • AIM

    726.18
    +1.20 (+0.17%)
     
  • GBP/EUR

    1.1533
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2201
    -0.0005 (-0.04%)
     
  • Bitcoin GBP

    22,093.76
    -140.55 (-0.63%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • DOW

    33,507.50
    -158.84 (-0.47%)
     
  • CRUDE OIL

    90.77
    -0.94 (-1.02%)
     
  • GOLD FUTURES

    1,864.60
    -14.00 (-0.75%)
     
  • NIKKEI 225

    31,857.62
    -14.90 (-0.05%)
     
  • HANG SENG

    17,809.66
    +436.63 (+2.51%)
     
  • DAX

    15,386.58
    +63.08 (+0.41%)
     
  • CAC 40

    7,135.06
    +18.82 (+0.26%)
     

Why Beam Therapeutics Stock Rocketed Higher This Week

Shares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week. Beam's sizable uptick seems to simply be a rebound following last week's 23% drop in its share price. Clinical-stage biotech stocks have been extremely volatile this year, thanks to rising interest rates, geopolitical turmoil, and investors' general aversion to risk right now.